CVS Health (CVS) reached a proposed settlement with the Federal Trade Commission regarding insulin pricing allegations, marking potential progress in the agency’s broader case against major pharmacy benefit managers. The settlement could provide a roadmap for resolving similar disputes with other industry players and reduce regulatory overhang on the healthcare sector.
Key Takeaways
- CVS reaches proposed FTC settlement on insulin pricing
- Express Scripts already settled for landmark $7 billion patient savings
- Negotiations continue with UnitedHealth’s Optum Rx PBM unit
Settlement Progress
The FTC disclosed “significant progress” in settlement talks with CVS Health’s Caremark and UnitedHealth Group’s (UNH) Optum Rx following a comprehensive agreement with Cigna’s (CI) Express Scripts 1. The Express Scripts settlement, finalized in February, requires fundamental business practice changes expected to save patients up to $7 billion over 10 years on insulin costs alone.
CVS said the company is “engaged in good-faith negotiations with the FTC, aimed at avoiding any prolonged litigation so that CVS Caremark can keep its focus on what it does best: making prescription drugs more affordable for Americans” 1. UnitedHealth declined to comment on ongoing discussions.
Regulatory Background
The FTC filed administrative complaints in September 2024 against the three largest pharmacy benefit managers-CVS’s Caremark, Express Scripts, and UnitedHealth’s Optum Rx-alleging anticompetitive rebating practices that artificially inflated insulin prices 2. These companies collectively control approximately 80% of U.S. prescription processing.
The agency’s case centers on allegations that PBMs created a “perverse” rebate system prioritizing high-rebate drugs over lower-cost alternatives, ultimately harming patients whose out-of-pocket costs are tied to inflated list prices. CVS also faces a separate $37.76 million settlement with the Justice Department for over-dispensing insulin pens to government healthcare program patients 3.
Express Scripts Precedent
The Express Scripts settlement established key reforms including stopping preference for expensive drug versions over cheaper identical alternatives, basing patient costs on net prices rather than inflated list prices, and implementing transparent pharmacy reimbursement models 4. FTC Chairman Andrew Ferguson called it a “clear testament to the Trump-Vance FTC’s focus on lowering healthcare costs for American patients” 5.
The settlement also requires Express Scripts to provide access to the “TrumpRx” platform and reshore its group purchasing organization from Switzerland to the United States, bringing over $750 billion in purchasing activity back domestically 5.
Market Implications
Healthcare reform advocates view the Express Scripts settlement as a potential watershed moment for PBM industry changes. Patient advocacy groups praised the structural reforms while emphasizing that drug manufacturers also bear responsibility for initial price-setting decisions 6.
The FTC extended its case timeline through March to allow for continued settlement negotiations, with evidentiary hearings now scheduled for August if agreements cannot be reached 1. The agency’s actions represent the most significant regulatory challenge to PBM business models in years.
Not investment advice. For informational purposes only.
References
1Paige Minemyer (March 5, 2026). “FTC seeing ‘progress’ in discussions with Optum, Caremark in insulin case”. Fierce Healthcare. Retrieved March 24, 2026.
2“Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin)”. Federal Trade Commission. Retrieved March 24, 2026.
3“U.S. Attorney Announces $37.76 Million Settlement With CVS For Over-Dispensing Insulin Pens To Patients”. U.S. Department of Justice. Retrieved March 24, 2026.
4Luke Sullivan (February 19, 2026). “In FTC Settlement, Cigna Agrees to Change Some PBM Business Practices, Charge Customers Less for Insulin”. Healthcare Uncovered. Retrieved March 24, 2026.
5“FTC Secures Landmark Settlement with Express Scripts to Lower Drug Costs for American Patients”. Federal Trade Commission. Retrieved March 24, 2026.
6“STATEMENT: P4ADNow Responds to FTC Settlement Addressing PBM Insulin Price-Gouging”. Patients For Affordable Drugs Now. Retrieved March 24, 2026.